Abstract
Activated protein C resistance (APCR) describes a hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). This results in an increased risk of venous thrombosis, including deep vein thrombosis and pulmonary embolism. Protein C is a natural anticoagulant that is synthesized in the liver and is activated to APC via proteolysis. APC then degrades Factors Va and VIIIa. APCR describes the reduced inability of APC to cleave Factors Va and VIIIa, which therefore promotes increased thrombin generation and potentially leads to a prothrombotic state. APCR may be hereditary or acquired. The most common hereditary defect is due to mutations in Factor V, predominantly the Factor V Leiden [FVL] mutation—a G1691A missense mutation at Arginine 506 that results in its replacement by a glutamine [R506Q] and the abolition of an APC inactivation cleavage site in Factor Va. Laboratory testing for APCR may be undertaken by a variety of methods, but this chapter describes an automated procedure using a commercial Russell Viper Venom-based clotting assay, and using CS-5100 and STA-R analyzers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Dahlback B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci 90:1004–1008
Coppola A, Tufano A, Cerbone AM, Di Minno G (2009) Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost 35:683–694
Lippi G, Danese E, Favaloro EJ, Montagnana M, Franchini M (2015) Diagnostics in venous thromboembolism: from origin to future prospects. Semin Thromb Hemost 41:374–381
Bertina RM, Koeleman BPC, Koster T et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 69:64–67
Voorberg J, Roelse J, Koopman R et al (1994) Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 343:1535–1536
Zoller B, Dahlback B (1994) Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536–1538
Zoller B, Svensson PJ, He X, Dahlback B (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94:2521–2524
Favaloro EJ, Mirochnik O, McDonald D (1999) Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT- than APTT- based assays. Br J Biomed Sci 56:23–33
Favaloro EJ, Orsag I, Bukuya M, McDonald D (2002) A nine-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. Pathology 34:348–355
Graf LL, Welsh CH, Qamar Z, Marlar RA (2003) Activated protein C resistance assay detects thrombotic risk factors Other than factor V Leiden. Am J Clin Pathol 119:52–60
Favaloro EJ, Mohammed S, Pati N, Manyuk H, McDonald D (2011) A clinical audit of congenital thrombophilia investigation in tertiary practice. Pathology 43:266–272
Favaloro EJ (2006) More on ‘universal’ versus ‘selected’ screening for thrombophilia: the hidden costs of false-positive diagnosis. Br J Haematol 134:239–240
Favaloro EJ, McDonald D, Lippi G (2009) Laboratory evaluation of thrombophilia: the good, the bad and the ugly. Semin Thromb Hemost 35:695–710
Favaloro EJ (2014) The futility of thrombophilia testing. Clin Chem Lab Med 52:499–503
Favaloro EJ, Lippi G (2017) Interference of direct oral anticoagulants (DOACs) in hemostasis assays: high potential for diagnostic false positives and false negatives. Blood Transfus. doi:10.2450/2016.0301-16
Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L (2006) Activated protein C resistance: the influence of ABO-blood group, gender and age. Thromb Res 117:665–670
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Mohammed, S., Favaloro, E.J. (2017). Laboratory Testing for Activated Protein C Resistance (APCR). In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7196-1_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7194-7
Online ISBN: 978-1-4939-7196-1
eBook Packages: Springer Protocols